Histocompatibility Antigens

Question 1

The MHC (also called the human leukocyte antigen [HLA] complex) is encoded on human chromosome __.

Answer 1

The MHC (also called the human leukocyte antigen [HLA] complex) is encoded on human chromosome 6.

(Henry’s 24th ed. p. 896)

Question 2

The MHC (also called the ___________________ [HLA] complex) includes class I molecules (HLA __, __, and __), class II molecules (HLA __, __, and __), and the intervening class III molecules of some complement components and TNF-__ and TNF-__.

Answer 2

The MHC (also called the human leukocyte antigen [HLA] complex) includes class I molecules (HLA A, B, and C), class II molecules (HLA DP, DQ, and DR), and the intervening class III molecules of some complement components and TNF-α and TNF-β.

(Henry’s 24th ed. p. 896)

Question 3

One of the most important clinical uses of HLA typing involves matching potential organ or tissue donors with recipients who are in need of a transplant.

Another significant clinical application is seen in the typing of affected patients and their family members to establish their risk for developing some diseases that are associated with particular HLA types (e.g., ankylosing spondylitis with HLA ___).

Still another use of HLA typing involves providing matched _______ for patients who have become refractory to _______transfusions as the result of HLA antibody formation after exposure to multiple donors (e.g., following transfusion support for chemotherapy or hematopoietic progenitor cell transplantation).

Answer 3

One of the most important clinical uses of HLA typing involves matching potential organ or tissue donors with recipients who are in need of a transplant.

Another significant clinical application is seen in the typing of affected patients and their family members to establish their risk for developing some diseases that are associated with particular HLA types (e.g., ankylosing spondylitis with HLA B27).

Still another use of HLA typing involves providing matched platelets for patients who have become refractory to platelet transfusions as the result of HLA antibody formation after exposure to multiple donors (e.g., following transfusion support for chemotherapy or hematopoietic progenitor cell transplantation).

(Henry’s 24th ed. p. 896)